A Short Review on Cancer and Moringa Oleifera Leaves Treatment: Review Article

Daigo Hirao

doi:10.58372/2835-6276.1232

Authors

Daigo Hirao

DOI:

https://doi.org/10.58372/2835-6276.1232

Keywords:

Moringa Oleifera, Cancer Treatment, Antibody properties, alternative medicine, lower and middle income country

Abstract

Cancer remains a significant global health burden, particularly in low- and middle-income countries (LMICs) where access to comprehensive treatment is limited. This review explores the potential of Moringa oleifera (MO) as a complementary therapeutic option in cancer care. Known for its rich composition of bioactive compounds, including isothiocyanates and glucosinolates, MO demonstrates promising anticancer properties, notably in inhibiting cell proliferation and inducing apoptosis in various cancer cell types. Studies reveal that MO leaf extracts can inhibit tumor growth and support immune modulation, offering a natural, cost-effective alternative to conventional treatments. This review aims to summarize existing research on MO’s anticancer efficacy, assess its potential for integration into treatment regimens, and highlight its implications for expanding accessible cancer therapies worldwide.

References

Mortality, G. B. D. (2015). Causes of Death C. Causes of Death C. Global, regional, and national age sex specific all cause and cause specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the global burden of disease study. Lancet, 117.

WHO. (2023, September). Noncommunicable diseases. Retrieved from WHO: https://www.who.int/en/news-room/fact-sheets/detail/noncommunicable-diseases

Bray, F., Soerjomataram, I., Gelband, H., Jha, P., Sankaranarayanan, R., & Horton, S. (2015). Cancer: disease control priorities. In The Changing Global Burden of Cancer: Transitions in Human Development and Implications for Cancer Prevention and Control. Retrieved from World Bank Group: https://documents.worldbank.org/en/publication/documents-reports/documentdetail/547531468190151195/disease-control-priorities-third-edition-cancer

Bray, F., Laversanne, M., Weiderpass, E., & Soerjamataram, I. (2021, June). The ever-increasing importance of cancer as a leading cause of premature death worldwide.

Catoe, H., Jarvis, J., Gupta, S., Ginsubrg, O., & Lopes, G. (2017, May). The Road to Addressing Noncommunicable Diseases and Cancer in Global Health Policy.

KiPPRA. (2021, January). Cancer as a Non-Communicable Disease and the Status of Cancer Control in Kenya.

Montagnana, M., & Lippi, G. (2017, July). Cancer diagnostics: current concepts and future perspectives.

WHO. (2018). Global Health Estimates 2016: disease burden by cause, age, sex, by country and by region, 2000–. Retrieved from WHO: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates

Canadian Cancer Society. (2023). How cancer starts, grows and spreads.

National Library of Medicine. (2000). The Development and Causes of Cancer.

Shrime, M., Alkire, B., Grimes, C., Chao, T., Poenaru, D., & Verguet, S. (2017, June). Cost-Effectiveness in Global Surgery: Pearls, Pitfalls, and a Checklist.

Lentz, R., Benson, A. I., & Kircher, S. (2019, July). Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies.

Ehsan, A.N.; Wu, C.A.; Minasian, A., Singh, T., Bass, M., Pace, L., Ibbotson, G., . . . Mekary, R. (2023, February 8). Financial Toxicity Among Patients With Breast Cancer Worldwide.

Ward, Z., Scott, A., Hricak, H., & Atun, R. (2021, March). Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis.

Chen, S., Cao, Z., Prettner, K., Kuhn, M., Yang, J., Jiao, L., . . . Wang, C. (2023, February). Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050.

OHSU. (2020). Social and Emotional Side Effects of Cancer. Retrieved from OHSU Knight Cancer Institute

MD Anderson Cancer Center. (2020). Social & Emotional Impacts of Cancer. Retrieved from MD Anderson Cancer Center

Baade, P., Dasgupta, P., Aitken, J., & Turrell, G. (2011, September). Distance to the closest radiotherapy facility and survival after a diagnosis of rectal cancer in Queensland.

Carriere, R., Adam, R., Fielding, S., Barlas, R., Ong, Y., & Murchie, P. (2018, September). Rural dwellers are less likely to survive cancer - An international review and meta-analysis.

van der Kruk, S., Butow, P., Mesters, I., Boyle, T., Olver, I., White, K., . . . Gunn, G. (2021, August). Psychosocial well-being and supportive care needs of cancer patients and survivors living in rural or regional areas: a systematic review from 2010 to 2021.

National Cancer Institute. (2024, May). Common Cancer Types. Retrieved from National Cancer Institute

National Cancer Institute. (2024). Cancer Stat Facts: Common Cancer Sites. Retrieved from National Cancer Institute

Cancer Research UK. (2019). Cancer incidence for common cancers. Retrieved from Cancer Research UK

National Cancer Institute. (2024, May 29). Understanding Cancer Prognosis. Retrieved from National Cancer Institute

Huang, S., Yang, J., Fong, S., & Zhao, Q. (2019, August). Mining Prognosis Index of Brain Metastases Using Artificial Intelligence.

Gaur, K., & Jagtap, M. (2022, November). Role of Artificial Intelligence and Machine Learning in Prediction, Diagnosis, and Prognosis of Cancer.

Kakimi, K., Karasaki, T., Matsushita, H., & Sugie, T. (2017). Advances in personalized cancer immunotherapy.

Esteva, F. (2004). Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer.

Dede, Z., Tumer, K., Kan, T., & Yucel, B. (2023, March). Current Advances and Future Prospects in Cancer Immunotherapeutics.

Mattheolabakis, G., Rigas, B., & Constantinides, P. (2012, October). Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives.

Stewart, D., Winnike, J., McRitchie, S., Clark, R., Pathmasiri, W., & Sumner, S. (2017, September). Metabolomics analysis of hormone-responsive and triple-negative breast cancer cell responses to paclitaxel identify key metabolic differences.

Anand, U., Dey, A., Chandel, A., Sanyal, R., Mishra, A., Pandey, D., . . . Pérez, J. (2022, March). Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.

WHO. (2023, July). Tobacco. Retrieved from WHO: https://www.who.int/news-room/fact-sheets/detail/tobacco

Mao, J., Pillai, G., Andrade, C., Ligibel, J., Basu, P., Cohen, L., . . . Ghelman, R. (2021, November). Integrative oncology: Addressing the global challenges of cancer prevention and treatment. Retrieved from American Cancer Society

National Cancer Institute. (2024, August 14). Cancer Prevention Research. Retrieved from National Cancer Institute

Madi, N., Dany, M., Abdoun, S., & Usta, J. (2016). Moringa oleifera's nutritious aqueous leaf extract has anticancerous effects by compromising mitochondrial viability in an ROS-dependent manner.

Ravani, A., Prasad, R., Gajera, R., & Joshi, D. (2017, October). Potentiality of Moringa oleifera for food and nutritional security-A review.

Berkovich, L., Earon, G., Ron, I. R., Vexler, A., & Lev-Ari, S. (2013, August). Moringa Oleifera aqueous leaf extract down-regulates nuclear factor-kappaB and increases cytotoxic effect of chemotherapy in pancreatic cancer cells.

Al-Asmari, A., Albalawi, S., Athar, M., Khan, A., Al-Shahrani, H., & Islam, M. (2015, August). Moringa oleifera as an anti-cancer agent against breast and colorectal cancer cell lines.

Singh, J., Gautam, D., Sourav, S., & Sharma, R. (2022, November 15). Role of Moringa oleifera Lam. in cancer: Phytochemistry and pharmacological insights. Retrieved from Wiley Online Library.

Kim, Y., Jaja-Chimedza, A., Merrill, D., Mendes, O., & Raskin, I. (2018). A 14-day repeated-dose oral toxicological evaluation of an isothiocyanate-enriched hydro-alcoholic extract from Moringa oleifera Lam. seeds in rats. . Retrieved from ScienceDirect

Maiyo, F., Moodley, R., & Singh, M. (2016). Cytotoxicity, antioxidant and apoptosis studies of quercetin-3-O glucoside and 4-(β-D-glucopyranosyl-1→ 4-α-L-rhamnopyranosyloxy)-benzyl isothiocyanate from Moringa oleifera.

Antonini, E., Iori, R., Ninfali, P., & Scarpa, E. (2017, November). A Combination of Moringin and Avenanthramide 2f Inhibits the Proliferation of Hep3B Liver Cancer Cells Inducing Intrinsic and Extrinsic Apoptosis.

Wang, C., Wu, R., Sargsyan, D., Zheng, M., Li, S., Yin, R., . . . Kong, A.-N. (2019, June). CpG methyl-seq and RNA-seq epigenomic and transcriptomic studies on the preventive effects of Moringa isothiocyanate in mouse epidermal JB6 cells induced by the tumor promoter TPA.

Wu, Y.-Y., Xu, Y.-M., & Lau, A. (2021). Anti-Cancer and Medicinal Potentials of Moringa Isothiocyanate.

Parvathy, M., & Umamaheshwari, A. (2008). Cytotoxic effect of Moringa oleifera leaf extracts on human multiple myeloma cell lines.

Khalafalla, M., Abdellatef, E., Dafalla, H., Nassrallah, A., Aboul-Enein, K. M., Lightfoot, D., . . . El-Shemy, H. (2016). Active principle from Moringa oleifera Lam leaves effective against two leukemias and a hepatocarcinoma.

Jung, I., Lee, J., & Kang, S. (2015, July). A potential oral anticancer drug candidate, Moringa oleifera leaf extract, induces the apoptosis of human hepatocellular carcinoma cells.